On the other hand, ivosidenib (IDH1 inhibitor) and enasidenib (IDH2 inhibitor) as monotherapies have yielded ~40% response rates and median OS of ~12 months in patients with AML harboring these mutations (12, 13, 51, 52) (Table 3). Here, IDH1 is linked to acute myeloid leukemia.